# Orelabrutinib in the Treatment of Relapsed/Refractory AIHA

> **NCT07453368** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia (AIHA)

## Interventions

- **DRUG:** Orelabrutinib-50
- **DRUG:** Orelabrutinib-100
- **DRUG:** Orelabrutinib-150

## Key facts

- **NCT ID:** NCT07453368
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453368, "Orelabrutinib in the Treatment of Relapsed/Refractory AIHA". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT07453368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*